Suppr超能文献

现代 G 蛋白偶联受体药物发现的关键方面。

Key aspects of modern GPCR drug discovery.

机构信息

Bioscience, Medicinal Chemistry, Pharmacology and Protein Science Departments, Sygnature Discovery Ltd, BioCity, Pennyfoot Street, Nottingham NG1 1GR, UK.

Bioscience, Medicinal Chemistry, Pharmacology and Protein Science Departments, Sygnature Discovery Ltd, BioCity, Pennyfoot Street, Nottingham NG1 1GR, UK.

出版信息

SLAS Discov. 2024 Jan;29(1):1-22. doi: 10.1016/j.slasd.2023.08.007. Epub 2023 Aug 23.

Abstract

G-protein-coupled receptors (GPCRs) are the largest and most versatile cell surface receptor family with a broad repertoire of ligands and functions. We've learned an enormous amount about discovering drugs of this receptor class since the first GPCR was cloned and expressed in 1986, such that it's now well-recognized that GPCRs are the most successful target class for approved drugs. Here we take the reader through a GPCR drug discovery journey from target to the clinic, highlighting the key learnings, best practices, challenges, trends and insights on discovering drugs that ultimately modulate GPCR function therapeutically in patients. The future of GPCR drug discovery is inspiring, with more desirable drug mechanisms and new technologies enabling the delivery of better and more successful drugs.

摘要

G 蛋白偶联受体(GPCRs)是最大和最多样化的细胞表面受体家族,具有广泛的配体和功能。自 1986 年首次克隆和表达第一个 GPCR 以来,我们已经了解到很多关于发现此类受体的药物,现在已经清楚地认识到 GPCR 是批准药物中最成功的靶标类别。在这里,我们带领读者了解从靶标到临床的 GPCR 药物发现之旅,重点介绍发现最终在患者中调节 GPCR 功能的治疗药物的关键经验、最佳实践、挑战、趋势和见解。GPCR 药物发现的未来令人鼓舞,更理想的药物机制和新技术使更好、更成功的药物得以交付。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验